TOKYO, Sept 27 (Reuters) – Japan has permitted GlaxoSmithKline (GSK.L) and Vir Biotechnology’s (VIR.O) Sotrovimab as an antibody therapy for coronavirus, Well being Minister Norihisa Tamura stated on Monday.
The antibody therapy is for gentle to reasonable COVID-19 circumstances which don’t require oxygen supplementation, GSK stated when it utilized for fast-track approval this month.
Reporting by Makiko Yamazaki, enhancing by Louise Heavens
Our Requirements: The Thomson Reuters Trust Principles.
